Neuromagen Pharma Announces the Approval of a NIS 1.8M Budget from the Israel Innovation Authority R&D Fund Incentive Program
BEER-SHEVA, Israel, March 21, 2022 /PRNewswire/ — Neuromagen Pharma Ltd., a company developing a new class of drugs for the treatment of degenerative and senescence-associated diseases, announced today the approval by the Israel Innovation Authority (IIA) of a NIS 1.3 million grant (75%…
Comments Off on
Neuromagen Pharma Announces the Approval of a NIS 1.8M Budget from the Israel Innovation Authority R&D Fund Incentive Program